Stryker Corporation

New York Stock Exchange
Back to all articles
Bullish +75

Worldwide Healthcare Trust outperforms benchmark; praises AstraZeneca

📈 Worldwide Healthcare Trust reported a net asset value per share of 371.0 pence as of March 31, representing a 9.3% increase from the previous year.

📊 The fund achieved a NAV total return of 10.0% for the financial year ended March 31, significantly outperforming its MSCI World Health Care index benchmark which returned just 1.8%.

💊 AstraZeneca PLC was identified as the top contributor to portfolio performance, with the London-based pharma giant being the only Europe-based company in the fund's top five contributors.

🔬 Management praised AstraZeneca for solidifying its status as a premier global player with leading franchises in oncology, respiratory, rare disease, and cardiovascular disease.

⚠️ Stryker Corp was the top detractor from performance, pressured by a macro rotation out of MedTech stocks and investor skepticism regarding volume growth despite an 11.4% net sales increase in Q4.

🔍 Other notable detractors included Vertex Pharmaceuticals Inc, Tokyo-based Daiichi Sankyo Co Ltd, UnitedHealth Group Inc, and Boston Scientific Corp.

🤝 Merger and acquisition activity was cited as a meaningful contributor to the fund's overall performance during the reported period.

🌐 The firm noted that US healthcare policy uncertainty lifted late in 2025, leading biotechnology and pharmaceutical sub-sectors to begin outperforming.

👴 Doug McCutcheon, the current Chair of Worldwide Healthcare, announced he will retire after the company's annual general meeting on July 14.

🔄 William Hemmings is set to succeed Doug McCutcheon as the new Chair following his retirement at the upcoming AGM.

📉 Shares in Worldwide Healthcare were trading 0.3% higher at 346.88 pence each on Friday morning in London.

🌍 The portfolio manager and board remain positive on the long-term outlook for global equities, particularly within the global healthcare sector.

💰 Large cap pharmaceutical companies are facing patent expiry pressures, prompting heavy investment in innovative pipelines and continued M&A activity in biotechnology.

📉 The fund's benchmark is the MSCI World Health Care index on a net total return sterling adjusted basis.

🏥 The top five contributors included GC Oncology, Exact Sciences, Avidity Biosciences, and Apellis Pharmaceutical alongside AstraZeneca.

Bullish Signals
  • Worldwide Healthcare Trust's net asset value per share reached 371.0 pence as of March 31, representing a strong 9.3% increase from the previous year.
  • The fund delivered a NAV total return of 10.0% for the financial year ended March 31, significantly outperforming its benchmark MSCI World Health Care index which returned only 1.8%.
  • AstraZeneca was identified as the top contributor to portfolio performance, solidifying its status with leading franchises in oncology, respiratory, rare disease, and cardiovascular disease.
  • The company highlighted an impressive breadth of innovation including a plethora of announced phase 3 clinical trials and a portfolio of 16 distinct blockbuster medicines.
  • Merger & acquisition activity was noted as a meaningful contributor to the fund's overall performance.
  • US healthcare policy uncertainty lifted late in 2025, leading biotechnology and pharmaceutical sub-sectors to begin outperforming.
  • The board remains positive on the long-run outlook for global equities and specifically for the global healthcare sector.
  • Large cap pharmaceutical companies are investing heavily in innovative pipelines due to patent expiry pressures, creating a strong incentive for continued M&A activity in the biotechnology sector where valuations remain attractive.
Risk Factors
  • Stryker Corp was identified as the top detractor in the portfolio due to investor skepticism regarding volume growth, despite a reported fourth quarter net sales increase of 11.4%.
  • The stock pressure on Stryker was exacerbated by macro rotation out of MedTech stocks and the 'Boston Scientific Effect', highlighting the sector's vulnerability to sudden shifts in investor sentiment regarding hospital capital expenditures.
  • Doug McCutcheon noted that large cap pharmaceutical companies continue to face significant patent expiry pressures, which forces them to invest heavily in innovative pipelines.
Full Analysis
Worldwide Healthcare Trust PLC reported that AstraZeneca PLC was its top contributor to portfolio performance for the financial year ended March 31, with net asset value per share reaching 371.0 pence, a 9.3% increase from the prior year's 339.5 pence. The trust achieved a NAV total return of 10.0%, significantly outperforming its MSCI World Health Care index benchmark which returned just 1.8%. AstraZeneca was highlighted as the premier global diversified pharmaceutical player with leading franchises in oncology, respiratory, rare disease, and cardiovascular disease, supported by a portfolio of 16 distinct blockbuster medicines and numerous phase 3 clinical trials. Conversely, surgical equipment firm Stryker Corp served as the top detractor due to macro rotation out of MedTech stocks and investor skepticism regarding volume growth, despite a fourth quarter net sales increase of 11.4%. Other notable contributors included GC Oncology, Exact Sciences, Avidity Biosciences, and Apellis Pharmaceutical, while Vertex Pharmaceuticals, Daiichi Sankyo, UnitedHealth Group, and Boston Scientific were among the top detractors. The trust's chair, Doug McCutcheon, noted that merger and acquisition activity was a meaningful contributor to performance and expressed a positive long-term outlook for global equities and the healthcare sector, citing supportive US regulatory environments and attractive valuations in biotechnology.